


What is The Aim of HDClarity?

TO ADVANCE HD RESEARCH

COLLECT: We are building a collection of high-quality cerebrospinal fluid (CSF), plasma and serum samples across 8 study groups for evaluation of biomarkers and pathways that will enable the development of novel treatments for Huntington's disease (HD):



CSF is an ideal fluid compartment for assessing HD biomarkers, particularly pharmacodynamic markers, due to its proximity to the brain. High quality plasma and serum samples are also collected matching the CSF collections, which will be used to evaluate biomarkers and pathways of relevance to HD research.


HDClarity samples are processed, logged and deposited for long-term storage at BioRep s.r.l. For more information, please see HDClarity website at <https://hdclarity.net/>

DISTRIBUTE: Samples can be requested by investigators around the world, allowing them to conduct groundbreaking research to identify new biomarkers and develop treatments for HD.

To request HDClarity samples for your research please see information at: <https://enroll-hd.org/for-researchers/access-data-biosamples>.

What Does HDClarity Participation Involve?


Participants attend annually and take part in two visits (Screening and Sampling) within a 30-day window. Some may attend an optional Repeat Sampling visit 4-8 weeks later:



In total, we hope to enroll **2500** individuals.

How Many HDClarity Visits Have Been Conducted So Far?

In total, we have completed **1020** Screening visit **873** Sampling visits, and **128** Optional Repeat Sampling visits.



Feb 08, 2024

HDClarity
A multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington's disease


How Safe Is HDClarity Participation?

Very safe! A recent study found that after nearly **600** spinal taps, the most common side effect is a mild or moderate headache, which soon gets better. Only one severe adverse event was reported, corresponding to **0.17%** of the total number of sampling visits.

Where Are HDClarity Sites Located?


HDClarity has continued to expand and is now open in **34** clinical sites, across **8** nations worldwide.

We are actively working to commence the study at more sites across Australasia, Europe, North and South America.



Third dataset release from HDClarity PDS3 is now available!

HDClarity PDS3 contains data from **673** study participants and includes **832** study visit packages, each associated with one or more successfully collected CSF samples.



PDS3 is the largest longitudinal collection of high-quality CSF and blood ever assembled in HD, carefully curated and accompanied by detailed phenotypic data. It will enable a new generation of innovative scientific projects at a critical time for the development of novel therapeutics.

The HDClarity PDS3 dataset and associated biosamples are made available via the Enroll-HD platform; to access these resources, please visit the Access page on the Enroll-HD website.

How are HDClarity Samples Being Used in Research?

Publicly available biomarker datasets derived from HDClarity samples

- CSF biomarker assay results, N=220. Neurofilament light, haemoglobin, total protein, mutant huntingtin, total huntingtin
- Somalogic proteomic data, N=579. Over 7,600 protein analytes in CSF and plasma

Selected publications and presentations using HDClarity data

- Pflzer et al. "Alterations in metal homeostasis occur prior to canonical markers in Huntington disease." *Scientific Reports* 12.1 (2022): 10373.
- Rodrigues et al. "Safety and feasibility of research lumbar puncture in Huntington's disease: The HDClarity cohort and bioresource." *Journal of Huntington's Disease* 11.1 (2022): 59-69.
- Hassan et al. "Lumbar puncture safety and tolerability in premanifest and manifest Huntington's disease: a multi-analysis cross-sectional study." *Scientific Reports* 12.1 (2022): 18377.
- Niels Skotte. "Biofluid biomarker discovery in HD – Current possibilities and limitations" – HD Therapeutics Conference 2023
- William Griffiths. "Cholesterol and oxysterols as biomarkers for Huntington's disease?" – HD Therapeutics Conference 2023
- Natalia Kalinava. "Optimizing assays for accurate reliable measurement of NfL and clinical validation of the measurements" – HD Therapeutics Conference 2023
- Jim Rosinsky. "Multi-omic profiling of people with Huntington's disease (PwHD) for biomarker discovery: The future is bright!" – HD Therapeutics Conference 2022

